Treatment Insights From RESPONSE: Ruxolitinib Therapy in Hydroxyurea-Resistant/Intolerant Disease

An expert discusses how the positive efficacy findings from the phase 3 RESPONSE trial, showing high rates of hematocrit control and spleen response with ruxolitinib vs standard therapy in hydroxyurea-resistant/intolerant polycythemia vera (PV), have enhanced the treatment approach for patients with inadequate response to hydroxyurea.

Video Player is loading.

Play Video

Play

Mute

Current Time 0:00

/

Duration 0:00

Loaded: 0%

0:00

Stream Type LIVE

Seek to live, currently behind liveLIVE

Remaining Time -0:00

 

1x

Playback Rate

Chapters

• Chapters

Descriptions

• descriptions off, selected

Captions

• captions settings, opens captions settings dialog
• captions off, selected

Audio Track

Fullscreen

This is a modal window.

Beginning of dialog window. Escape will cancel and close the window.

Text

ColorWhiteBlackRedGreenBlueYellowMagentaCyanTransparencyOpaqueSemi-Transparent

Background

ColorBlackWhiteRedGreenBlueYellowMagentaCyanTransparencyOpaqueSemi-TransparentTransparent

Window

ColorBlackWhiteRedGreenBlueYellowMagentaCyanTransparencyTransparentSemi-TransparentOpaque

Font Size

50%75%100%125%150%175%200%300%400%

Text Edge Style

NoneRaisedDepressedUniformDropshadow

Font Family

Proportional Sans-SerifMonospace Sans-SerifProportional SerifMonospace SerifCasualScriptSmall Caps

Reset restore all settings to the default valuesDone

Close Modal Dialog

End of dialog window.

Close Modal Dialog

This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.

EP: 1.A 68-Year-Old Woman Diagnosed With Primary Myelofibrosis

EP: 2.Molecular Profiling in MPNs: Enhancing Diagnostic Insights

EP: 3.JAK V617F Monitoring and Risk Assessment Tools: Optimizing Treatment Decisions in MPN

Now Viewing

EP: 4.Treatment Insights From RESPONSE: Ruxolitinib Therapy in Hydroxyurea-Resistant/Intolerant Disease

EP: 5.Advances in MPN Management: Insights From MANIFEST-2 and Beyond

EP: 6.Quality of Life in MPNs: Patient-Centered Factors That Shape Treatment Approaches

EP: 7.Academic Perspectives on the Evolving Treatment Landscape in MPNs

Video content above is prompted by the following:

The phase 3 RESPONSE trial findings showed high rates of hematocrit control and spleen response with ruxolitinib vs standard therapy in hydroxyurea-resistant/intolerant PV (Kiladjian et al. 2020 Lancet Haematol). How have these positive efficacy findings enhanced your treatment approach for patients with inadequate response to hydroxyurea?

Recent Videos

COMFORT Trials: Applying Evidence to Intermediate-Risk Myelofibrosis

Myelofibrosis Management: Clinical Approaches and Treatment Algorithms With Case-Based Application

Clinical Impact of COCOON: Advancing Dermatologic AE Management

Clinical Decision-Making Framework for Initiating Myelofibrosis Therapy

Clinical Approaches for Dermatologic AEs Associated With Amivantamab + Lazertinib in Advanced NSCLC

Prognostic Stratification on Myelofibrosis: From Models to Clinical Application

Ruxolitinib Therapy for cGVHD: Insights on Patient and Safety Monitoring

Personalized JAK Inhibitor Selection in Myelofibrosis: Clinical Characteristics, Molecular Profiles, and Treatment Sequencing

Advancing Treatment Paradigms in Myeloproliferative Neoplasms: From Molecular Pathogenesis to Patient-Tailored Therapy

Diagnostic Challenges in Myelofibrosis: Distinguishing Prefibrotic Disease